Wednesday, 19 Feb 2020

You are here

Biologic Agents have Equal Efficacy in Enthesitis and Dactylitis

A systematic review has shown that TNF inhibitors (TNFi) are equaled in efficacy by other biologic agents (ustekinumab, secukinumab, and ixekizumab) in psoriatic arthritis (PsA) patients with in dactylitis and enthesitis.

The literature review analyzed datafrom randomized controlled trials (RCTs) with TNFi (infliximab, golimumab, adalimumab), antiinterleukin- 12/23 (ustekinumab) and anti-interleukin-17 (secukinumab, ixekizumab).

The analysis was narrowed to 18 RCTs and 6981 patients.

The ability of the biologic to yield significant resolution of dactylitis at week 24 revealed the following risk ratios (RRs) versus placebo: 

  • TNFi: RR 2.57 (95% CI: 1.36-4.84)
  • Novel biologics RR 1.88 (95% CI: 1.33-2.65), respectively

Resolution of enthesitis at week 24 revealed:

  • TNFi: RR 1.93 (95% CI: 1.33-2.79)
  • Novel biologics: RR 1.95 (95% CI: 1.60-2.38)

Both the TNFi and novel biologic had overlapping ranges of ACR20 responses:

  • TNFi: RR=2.23, 95% CI: 1.60-3.11
  • Anti-IL-12/23 and IL-17 agents: RR=2.30, 95% CI 1.94-2.72)

Pooled analysis demonstrates agents targeting TNFi, IL-17, and IL-12/23 have equivalent efficacy in managing dactylitis and enthesitis in PsA patients.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Bimekizumab Effective in Active Psoriatic Arthritis

Interleukin 17 IIL-17) is important in the pathogenesis of psoriatic disease, with most current approaches targeting IL-17A. Now there is a noveal approach showing that dual neutralisation of IL-17A and IL-17F in psoriatic arthritis arthritis patients results in clinically significant improvement.

Upadacitinib Effective in Phase 3 Psoriatic Arthritis Study

Abbvie has announced top line results of their SELECT-PSA trial of upadacitinib (UPA), wherein both the 15 and 30 mg doses met the primary endpoint of ACR20 response at week 12 and demonstrated radiographic inhibition at week 24.

Which Biologics are Best in Psoriasis

A metanalysis of phase II, III and IV trials in moderate to severe plaque psoriasis suggests comparative efficacy biologic treatments, but that that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were shown to have the past skin (PASI) response rates.

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.

Best of 2019 - SEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?

The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.